Jump To Section
Featured Stories
Gilead Trial Pause Adds To Merck & Co’s HIV Concerns
The partners are halting recruitment out of “an abundance of caution,” but Gilead could decide to exit the alliance if islatravir cannot shake off safety concerns.
Chinese Biotechs Step Onto World Stage With Innovative Products, Competitive Prices
In a new landmark, Chinese firm BeiGene has posted greater quarterly sales of its cancer drug Brukinsa in the US than in China for the first time. Meanwhile, a growing number of innovative products developed in China are on the cusp of expansion into overseas markets.
New Player Joins Search For Effective Huntington's Therapies
Despite recent setbacks for Roche and Wave's respective antisense offerings, both those two firms and a number of other companies are trying a variety of approaches to find a treatment for Huntington's.
Coronavirus Spotlight
Research Sheds New Light On Coronavirus Origins, Early Wuhan Cases
New research by US-based Canadian scientist Michael Worobey sheds further light on the role of the Wuhan market in the human origins of SARS-CoV-2.
Rolling Coverage Of The Coronavirus Outbreak And The Biopharma Industry's Response Is Here.
Latest News
Scrip Podcast
Insights and perspectives on commercial, R&D,
deal-making and business strategy developments.
More Podcasts
Recent Tweets from Scrip
Infographics
Scorching COVID-19 Era Returns From India Biotech, Healthcare Funds Outpace The Globe
Early COVID-19 therapies including Gilead’s remdesivir, China-plus procurement policies, vaccine partnerships and a dovish stance by the central bank led to returns on India biotech and healthcare funds outperforming global returns. Meanwhile, funding for e-pharmacies and online consulting firms gathered pace.
Breast Cancer Trial Enrollment Illustrates Diversity Challenge
INFOGRAPHIC: Data on industry-sponsored breast cancer studies posted on ClinicalTrials.gov shows how much work remains for drug makers to ensure their studies enroll diverse populations.
Alzheimer’s Disease: Many Failures Before One Success
For Biogen/Eisai’s success with Aduhelm, there were 93 failures in the anti-amyloid field. Scrip took a look back at how the pipeline for amyloid-targeting Alzheimer’s drugs progressed over roughly the past decade to showcase exactly how difficult the Alzheimer’s space has been.
Commercial Explore this Topic
Remove Alert
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Commercial
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the prospects and plans for J&J’s pharma and oncology business; China looks more inward under new policies; an important US approval for Takeda; and Moderna’s co-founder shares tips on innovation.
Cambridge Vision Achieved, AstraZeneca Looks To Realize ‘Pipeline 2’ Ambitions
Having achieved a turnaround in its R&D and commercial fortunes, AstraZeneca’s hopes the opening of a new research center will herald its next wave of novel therapies.
3D Med, Alphamab Get First SubQ Immuno-Oncology Approval, In China
A landmark approval and domestic tie-up in China mark the fast innovation that is shaping the country’s health sector.
Tech Transfer Roundup: Athenex, PDS Align With National Cancer Institute On Oncology R&D
Athenex expands its portfolio of T-cell receptor therapy technology under NCI license agreement; PDS Biotechnology accesses institute’s TARP tumor antigen technology.
Finance Watch: Venture Capital Drives Record-Breaking Year For Cell And Gene Therapies
Private Company Edition: Recent VC financings across biopharma sectors include three major mega-rounds as Generate Biomedicines bringing in $370m, followed by $250m for Acelyrin and $125m for Chroma Medicine. Also, Treadwell raised a $91m series B and Ncardia brought in $60m-plus.
Takeda's Livtencity Approved For Refractory CMV Infection In Transplant Patients
Maribavir is the first antiviral agent targeting and inhibiting the pUL97 protein kinase, as well as Takeda's second new molecular entity approved by FDA this year.
Policy & Regulation Explore this Topic
Remove Alert
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Policy & Regulation
Pfizer/BioNTech’s Comirnaty Supply Agreements Unaffected Despite EU Green Light For Under-12s
Pfizer and BioNTech’s Comirnaty supply under existing agreements will continue as planned despite anticipated expansion into a new child sub-population in Europe.
Novo Nordisk Braced For China Insulin Scheme Impact
The value-based procurement scheme in China is about to be implemented on insulin products and while most of Novo Nordisk's therapies were included in the tender, price cuts are going to impact global sales growth by 3% next year.
Amryt's Wings Clipped By Delay For Butterfly Skin Drug Decision
The Irish firm needs to give regulators in the US more information on its epidermolysis bullosa therapy but is confident of address those requests from its "existing data within the time periods required," according to CEO Joe Wiley.
Research & Development
Remove Alert
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Research & Development
Cambridge Vision Achieved, AstraZeneca Looks To Realize ‘Pipeline 2’ Ambitions
Having achieved a turnaround in its R&D and commercial fortunes, AstraZeneca’s hopes the opening of a new research center will herald its next wave of novel therapies.
Pipeline Watch: Six Phase III Trial Starts Plus 19 New Approvals
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
J&J's Next Immunology Act Centers On Nipocalimab For Autoantibody-Driven Diseases
The company has ramped up a broad R&D program for the FcRn inhibitor in 11 autoantibody-driven disease areas.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.